Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage ...

The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...